Here is a **comprehensive pharmacological profile for peptide complex A-6** ‚Äî more properly known as **A6 (also √Ö6)**, a short urokinase-derived octapeptide (sequence *Ac-KPSSPPEE-NH‚ÇÇ*) that has been studied as an antineoplastic/anti-metastatic agent and in early clinical trials. Note: *A6 is a research and investigational compound ‚Äî it is not an approved drug in most countries.* ([cancer.gov][1])

---

## üìå **1. Mechanism(s) of Pharmacological Action**

**Primary actions identified in preclinical/clinical research:**

1. **Modulation of CD44 activity**

   * A6 binds to CD44 (a cell surface adhesion receptor), alters its conformation, inhibits tumor cell migration/invasion, and activates focal adhesion kinase (FAK) / MAPK signaling. ([PubMed][2])

2. **Anti-metastatic and anti-invasive effects**

   * A6 inhibits migration and metastasis of CD44-positive tumors in multiple models. ([PubMed][3])

3. **Anti-angiogenic properties**

   * Although less well quantified, A6 exhibited anti-angiogenic effects in early studies. ([PubMed][4])

4. **Anti-inflammatory and anti-osteoclast effects**

   * A6 attenuates LPS-induced osteoclastogenesis and bone destruction by modulating NF-Œ∫B, AMPK, and Akt pathways in macrophage/osteoclast models. ([PubMed][5])

5. **Cell signaling modulation**

   * The peptide has upstream effects on CD44-mediated pathways affecting adhesion, migration, and survival. ([PubMed][3])

---

## üïê **2. Pharmacokinetics (PK)**

### **Absorption & Time to Peak**

* After **subcutaneous (s.c.) administration in humans**, **time to peak plasma concentration (Tmax)** ~ **0.5‚Äì2.1 hours**. ([PubMed][4])

### **Half-Life (t¬Ω)**

* In healthy human volunteers after s.c. injection, **terminal half-life ~1.4‚Äì1.8 hours**. ([PubMed][4])

### **Elimination**

* A6 is eliminated largely **unchanged in urine** (~78‚Äì95% depending on dose and regimen). ([PubMed][4])

### **Bioavailability**

* Exact absolute bioavailability values (especially oral) have *not been published in peer-reviewed A6 human studies* ‚Äî but like most short peptides, A6 is likely poorly bioavailable orally unless modified (protease resistance, formulation strategies).
* In early human PK studies, only **subcutaneous administration was evaluated**. ([PubMed][4])

**Oral route:**

* Peptides like A6 are generally vulnerable to proteolytic digestion ‚Äî unless specifically engineered for oral delivery, oral bioavailability is likely *very low*. Research exists exploring exceptions for other peptides but not specific quantification for A6. ([patents.google.com][6])

---

## üíä **3. Dosage Information from Clinical Studies**

Human data exists only from early phase clinical trials:

### **Subcutaneous Dosing (Human Phase I)**

* Single doses: **15 mg up to 300 mg s.c.** were **safe and well-tolerated**. ([PubMed][4])
* Repeated s.c. dosing: **Up to 150 mg every 12 hours for 6 days** was tolerated. ([PubMed][4])

### **Clinical Oncology Trial Doses**

* In a randomized Phase II trial (ovarian cancer), daily s.c. injections of **150 mg (low) and 300 mg (high)** were used. ([PubMed][7])

### **Typical Research/Preclinical Doses (Animal Studies)**

* Murine tumor and bone loss models often used **~50‚Äì100 mg/kg s.c.** with biological effects reported. ([PubMed][2])

---

## ‚ö†Ô∏è **4. Safety, Toxicity & Maximum Tolerated Dose**

### **Human Safety Observations**

* **No dose-limiting toxicity was observed in early Phase I** trials up through 300 mg s.c. single dose. ([PubMed][4])
* No early immunogenic response (anti-A6 antibodies) detected. ([PubMed][4])

### **Toxic Dose / LD‚ÇÖ‚ÇÄ**

* **No published LD‚ÇÖ‚ÇÄ values** exist for humans or standard animal toxicology data in peer-reviewed literature for the native A6 peptide.
* As a short peptide with rapid elimination and no serious toxicity up to high doses in early human trials, its **acute lethal dose** is unknown, and toxicity thresholds are not defined.

‚ö†Ô∏è This means: **LD‚ÇÖ‚ÇÄ and toxicity curves are not established** ‚Äî and inferring them would be speculative and irresponsible.

---

## üìä **5. Summary Table**

| Parameter                     | Reported Value / Range                                          | Notes                                                    |
| ----------------------------- | --------------------------------------------------------------- | -------------------------------------------------------- |
| Sequence                      | Ac-KPSSPPEE-NH‚ÇÇ                                                 | 8-amino acid peptide derived from uPA. ([cancer.gov][1]) |
| Mechanism of Action           | CD44 modulation, anti-migration, anti-invasion, anti-angiogenic | Preclinical/clinical. ([PubMed][2])                      |
| Tmax (s.c.)                   | ~0.5‚Äì2.1 h                                                      | In healthy humans. ([PubMed][4])                         |
| T¬Ω (terminal)                 | ~1.4‚Äì1.8 h                                                      | Rapid clearance. ([PubMed][4])                           |
| Bioavailability               | **Not established (likely low orally)**                         | Only s.c. PK characterized. ([PubMed][4])                |
| Human safe dose (single)      | 15‚Äì300 mg s.c.                                                  | Phase I. ([PubMed][4])                                   |
| Human safe dose (repeat)      | Up to 150 mg s.c. every 12 h                                    | Short term. ([PubMed][4])                                |
| Dose in Phase II cancer trial | 150‚Äì300 mg s.c. daily                                           | Ovarian cancer. ([PubMed][7])                            |
| LD‚ÇÖ‚ÇÄ (animal/human)           | **Not established**                                             | No public data.                                          |
| Oral bioavailability          | **Not characterized**                                           | Likely negligible unless modified.                       |

---

## ‚ùó **Important Considerations & Limitations**

üîπ **No oral A6 PK data in humans** ‚Äî short peptides are generally poorly absorbed orally due to proteolysis. ([patents.google.com][6])
üîπ **Toxicology (LD‚ÇÖ‚ÇÄ, safety margins)** are not published ‚Äî clinical dosing tolerability is limited to early, controlled settings. ([PubMed][4])
üîπ Mechanism details are primarily preclinical; **clinical efficacy data are mixed and not definitive.** ([PubMed][7])
üîπ Quantitative dose‚Äìresponse curves (e.g., EC‚ÇÖ‚ÇÄ, IC‚ÇÖ‚ÇÄ for individual pathways in humans) are not generally available beyond cell models. ([PubMed][2])

---

## üìå **Summary**

A6 is a short peptide with **anti-metastatic, anti-migratory, anti-angiogenic and anti-inflammatory potential** acting mainly through **CD44 modulation** and related signaling pathways. It shows a **short half-life (~1‚Äì2 h)** after subcutaneous administration and **rapid renal elimination**. Human clinical data demonstrate safety up to hundreds of milligrams s.c., but **oral administration, bioavailability, and toxicity thresholds (LD‚ÇÖ‚ÇÄ) are not established**. ([PubMed][4])

If you want, I can help summarize typical **preclinical dose‚Äìeffect relationships** (e.g., IC‚ÇÖ‚ÇÄ/EC‚ÇÖ‚ÇÄ values for migration inhibition, signaling changes in cell models) in tabular form. Would you like that?

[1]: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/urokinase-derived-peptide-a6?utm_source=chatgpt.com "Definition of urokinase-derived peptide A6 - NCI Drug Dictionary - NCI"
[2]: https://pubmed.ncbi.nlm.nih.gov/21885863/?utm_source=chatgpt.com "A6 peptide activates CD44 adhesive activity, induces FAK and MEK phosphorylation, and inhibits the migration and metastasis of CD44-expressing cells - PubMed"
[3]: https://pubmed.ncbi.nlm.nih.gov/25870596/?utm_source=chatgpt.com "Modulation of CD44 Activity by A6-Peptide - PubMed"
[4]: https://pubmed.ncbi.nlm.nih.gov/15176647/?utm_source=chatgpt.com "Safety, tolerability and pharmacokinetics of subcutaneous A6, an 8-amino acid peptide with anti-angiogenic properties, in healthy men - PubMed"
[5]: https://pubmed.ncbi.nlm.nih.gov/28493442/?utm_source=chatgpt.com "uPA-derived peptide, √Ö6 is involved in the suppression of lipopolysaccaride-promoted inflammatory osteoclastogenesis and the resultant bone loss - PubMed"
[6]: https://patents.google.com/patent/CA2583716A1/en?utm_source=chatgpt.com "Oral dosage formulations of protease resistant polypeptides"
[7]: https://pubmed.ncbi.nlm.nih.gov/18760451/?utm_source=chatgpt.com "A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer - PubMed"
